Relay Therapeutics (RLAY) Invested Capital (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Invested Capital data on file, last reported at $642.2 million in Q1 2026.

• Quarterly Invested Capital fell 10.94% year-over-year to $642.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $642.2 million (down 10.94% YoY) and the FY2025 annual result came in at $567.1 million, down 27.09% from the prior year.
• Invested Capital advanced to $642.2 million in Q1 2026 per RLAY's latest filing, from $567.1 million in the prior quarter.
• Across five years, Invested Capital topped out at $999.8 million in Q3 2022 and bottomed at $567.1 million in Q4 2025.
• The 5-year median for Invested Capital is $777.8 million (2024), against an average of $767.3 million.
• The widest annual swing landed in 2022, when Invested Capital jumped 75.06%; it then declined 27.56% in 2025.
• Tracing RLAY's Invested Capital over 5 years: stood at $950.2 million in 2022, then retreated by 20.86% to $752.0 million in 2023, then gained by 3.43% to $777.8 million in 2024, then declined by 27.09% to $567.1 million in 2025, then gained by 13.25% to $642.2 million in 2026.
• Per Business Quant, the three latest RLAY Invested Capital figures stand at $642.2 million (Q1 2026), $567.1 million (Q4 2025), and $607.7 million (Q3 2025).

Peer Comparison